Intellia Therapeutics Presents Hereditary Angioedema Study Results
Intellia Therapeutics announced details about its presentation of four posters at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting, AAAAI, that took place this past weekend in Philadelphia, Pennsylvania. Title: Long-Term Durability and Safety of Lonvoguran Ziclumeran 50 mg in Patients with Hereditary Angioedema: Across the 32 patients, the mean monthly attack rate was consistently less than or equal to0.2, representing a mean reduction of 96% in HAE attacks from baseline through last follow-up. Of the 32 patients, 31 were both attack-free and LTP-free as of the data cutoff, with the attack-free and LTP-free periods ranging from 2 months to 3 years with follow-up ongoing. Title: Evolving Treatment Goals to Achieve Freedom from Attacks and Long-Term Prophylaxis Following a One-Time Treatment with Lonvoguran Ziclumeran: Of the 28 patients with greater than6 months of follow-up after receiving a one-time 50 mg treatment of lonvo-z in a pooled Phase 1/2 analysis, 86% were attack-free and LTP-free for greater than6 months, a timeframe suggested by patients to be clinically meaningful. Title: Quantitative Systems Biology Modeling Estimates Extent of Excessive Kallikrein Generation in Hereditary Angioedema Patients: In this model, an 85% reduction in prekallikrein was shown to reduce peak free kallikrein and peak bradykin to near normal ranges. This level of reduction in prekallikrein is consistent with what has been observed clinically with a 50 mg dose of lonvo-z
